Protein Supplements (Whey, Casein, Plant) & Essential Amino Acids (EAAs / Leucine)
Protein Supplements (Whey, Casein, Plant) & Essential Amino Acids (EAAs / Leucine) is classified under Group A (Evidence-Supported Sports Nutrition & Ergogenic Aids). While specific physiological and performance benefits are supported in peer-reviewed sports nutrition literature, dietary supplements are not universally safe, cannot replace whole-food nutrition, and carry real risks of undeclared prohibited-substance contamination (10–25% of uncertified commercial supplements). Always consult a qualified physician, pharmacist, or accredited sports dietitian.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Protein Supplements (Whey, Casein, Plant) & Essential Amino Acids (EAAs / Leucine)
Common Names, Synonyms & Classifications: Whey Protein Isolate/Concentrate; Micellar Casein; Soy/Pea Protein Isolate; Essential Amino Acids (EAAs); L-Leucine
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A08)
2. Pharmacological Class
Macronutrient Nitrogen & Essential Amino Acid Substrate; mTORC1 Myofibrillar Protein Synthesis Activator
3. Mechanism of Action
Provides all nine indispensable Essential Amino Acids (EAAs: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine) required for skeletal muscle remodelling and repair. Intracellular L-leucine (~2–3 g threshold per meal) binds Sestrin2 to activate the mechanistic Target of Rapamycin Complex 1 (mTORC1) signalling cascade (p70S6K and 4E-BP1 phosphorylation), stimulating myofibrillar and mitochondrial muscle protein synthesis (MPS) when combined with mechanical resistance or endurance training.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological/Physiological Effect: Stimulates post-exercise muscle protein synthesis and achieves positive net nitrogen balance. Proven Athletic Performance Benefit: Supports skeletal muscle hypertrophy, strength recovery, and lean mass preservation during caloric restriction when total daily dietary protein reaches 1.4–2.0 g/kg/day (distributed as 0.25–0.40 g/kg per feeding). Unsupported Claims: Isolated Branched-Chain Amino Acids (BCAAs: leucine, isoleucine, valine alone) without the remaining six EAAs cannot sustain maximal myofibrillar protein synthesis because substrate limitation of the other EAAs halts polypeptide elongation; whole food proteins (milk, curd, paneer, dal-cereal combinations, eggs, fish) are equally effective when total EAA and leucine targets are met.
5. Quality of Scientific Evidence
Evidence Assessment: High / Level A Consensus (ISSN Position Stand on Protein & Exercise; IOC Consensus Statement; ICMR-NIN Dietary Guidelines for Indians)
6. Approved Medical Uses (Where Applicable)
Medical nutrition therapy in protein-energy malnutrition, burns, trauma, post-surgical convalescence, and sarcopenia.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Used as convenient post-training nutrition when whole-food meals are impractical. CRITICAL CONTAMINATION & ADULTERATION RISK: Independent surveys in India and globally have identified commercial protein powders with: (1) 'amino spiking' (adding cheap glycine/taurine/melamine to inflate Kjeldahl nitrogen tests), (2) heavy metal contamination (lead, arsenic, cadmium), or (3) undeclared WADA-prohibited anabolic steroids or SARMs (e.g., stanozolol, methandienone, ostarine).
8. Adverse Effects & Serious Safety Risks
Lactose-induced bloating, flatulence, and osmotic diarrhoea with whey protein concentrate in lactose-intolerant individuals (whey isolate has <1% lactose); acne flares in some individuals sensitive to dairy insulinotropic peptides.
9. Contraindications & Precautions
Pre-existing chronic kidney disease (CKD not on dialysis, where protein restriction to ~0.8 g/kg/day is clinically indicated), hepatic encephalopathy, cow's milk protein allergy, or inborn aminoacidopathies (e.g., phenylketonuria [PKU], maple syrup urine disease).
10. Drug Interactions
High-protein meals and large neutral amino acids compete with oral Levodopa for intestinal and blood-brain barrier LAT1 transport, reducing Levodopa efficacy in Parkinson's disease.
11. Clinical & Laboratory Monitoring Considerations
Verify FSSAI license number, independent lab assay for true protein vs amino-spiking, heavy-metal testing, and batch-specific Informed-Sport / NSF anti-doping certification for competitive athletes.
12. Dependence, Misuse or Withdrawal Concerns
No dependence.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Regulated under FSSAI (Health Supplements, Nutraceuticals, Food for Special Dietary Use) Regulations, 2022, and ICMR-NIN Dietary Guidelines for Indians (2024), which caution against unnecessary high-dose protein powders in sedentary individuals.
14. Official WADA Prohibited-List Status
NOT PROHIBITED (Pure dietary proteins and the 20 standard proteinogenic amino acids are permitted at all times; athletes bear strict liability under the WADA Code if a contaminated supplement contains undeclared S1/S2/S6 prohibited substances).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026